Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • Find a professional representative
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • EPC Guidelines
      • PCT-EPO Guidelines
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • A glimpse of the planned activities
      • Kids’ collaborative art competition
      • 50 Leading Tech Voices
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Select Committee documents
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
            • Go back
            • Overview
            • BG - Federated Register Service
            • GB - Federated Register Service
            • NL - Federated Register Service
            • MK - Federated Register Service
            • ES - Federated Register Service
            • GR - Federated Register Service
            • SK - Federated Register Service
            • FR - Federated Register Service
            • MT - Federated Register Service
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • Find a professional representative
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • EPC Guidelines
        • Go back
        • Overview
        • Archive
      • PCT-EPO Guidelines
        • Go back
        • Overview
        • Archive
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
        • IP clinics
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Overview
      • 50 Leading Tech Voices
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
      • Surveys
        • Go back
        • Overview
        • Search services
        • Examination services, final actions and publication
        • Opposition services
        • Patent filings
          • Go back
          • Overview
          • Detailed methodology
          • Archive
        • Online Services
        • Patent information
          • Go back
          • Overview
          • Innovation process survey
        • Customer services
        • Filing services
        • Website
        • Survey on electronic invoicing
        • Companies innovating in clean and sustainable technologies
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/j110008eu1
  1. Home
  2. J 0008/11 (Sequence listing/DKFZ) 30-01-2013
Facebook Twitter Linkedin Email

J 0008/11 (Sequence listing/DKFZ) 30-01-2013

European Case Law Identifier
ECLI:EP:BA:2013:J000811.20130130
Date of decision
30 January 2013
Case number
J 0008/11
Petition for review of
-
Application number
10001596.5
IPC class
C12Q 1/68
G01N 33/50
Language of proceedings
EN
Distribution
DISTRIBUTED TO BOARD CHAIRMEN (C)

Download and more information:

Decision in EN 146.83 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Means and methods for diagnosing pancreatic cancer

Applicant name
Deutsches Krebsforschungszentrum
Opponent name
-
Board
3.1.01
Headnote
-
Relevant legal provisions
European Patent Convention Art 106(2)
European Patent Convention R 30
European Patent Convention R 103(1)(a)
Decision_President_dated 12 July 2007 concerning the filing of sequence listings
European Patent Convention R 27a 1973
European Patent Convention R 28 1973
Keywords
Sequence listing for prior-art sequence (not required)
Catchword
See points 2 to 19 of the reasons.
Cited decisions
J 0004/85
J 0033/89
J 0007/97
J 0007/11
Citing decisions
T 1967/20

I. The present appeal concerns a decision of the Receiving Section of the EPO, dispatched on 22 December 2010, refusing the applicant's requests that the invitation to remedy deficiencies pursuant to Rule 30(3) EPC be withdrawn and the late furnishing fee refunded.

II. European patent application 10001596.5 was filed on 17 February 2010 without a sequence listing. Its claim 1 was directed to a diagnostic method comprising, inter alia, the step of determining in a sample the amount of at least one biomarker selected from the biomarkers shown in Table 1 of the application. Table 1 listed 27 proteins with their names and database accession numbers. Page 3, lines 22 to 31 of the description contained the following passages:

"The term 'biomarker' as used herein refers to a polypeptide as shown in Table 1 or a fragment or variant of such a polypeptide being associated to the presence or absence of pancreatic cancer to the same extent as the well known polypeptides recited in Table 1. The polypeptide biomarkers listed in Table 1, preferably, encompass the polypeptides referred to by public Uni Prot Accession numbers as well as variants of said polypeptides having essentially the same immunological and/or biological properties. Variants include polypeptides differ [sic] in their amino acid sequence due to the presence of conservative amino acid substitutions. Preferably, such variants have an amino acid sequence being at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% identical to the amino acid sequences of the aforementioned specific polypeptides."

III. On 1 July 2010 the Receiving Section sent out an invitation to remedy deficiencies pursuant to Rule 30(3) EPC. It was indicated that the application as filed contained a sequence listing which did not comply with the relevant rules since it did not include all the sequences disclosed in the application. In an annex to this invitation, it was pointed out, on the one hand, that where the application referred to sequences which belonged to the prior art and could be found in generally accessible databases, it was not necessary to include such sequences in the sequence listing, and, on the other hand, that where prior-art sequences were mentioned in claims or constituted essential features of the invention, they should be given in the sequence listing. The applicant was invited to remedy the deficiency indicated and to pay the late furnishing fee.

IV. In its response, the applicant submitted a sequence listing and paid the late furnishing fee. However it requested that the invitation according to Rule 30(3) EPC be withdrawn and the late furnishing fee be refunded, and submitted legal arguments in support of these requests.

V. Following a communication by the Receiving Section giving reasons why the applicant's requests could not be accepted, the applicant submitted further arguments and conditionally requested an appealable decision. The Receiving Section then dispatched the decision from which the present appeal lies.

VI. In its statement of grounds of appeal, the appellant requested that

- the decision of the Receiving Section be set aside,

- the invitation to remedy deficiencies be withdrawn,

- the late furnishing fee be refunded, and

- the appeal fee be reimbursed.

As an auxiliary measure, oral proceedings were requested.

VII. The arguments submitted by the appellant in its statements of grounds of appeal and before the Receiving Section can be summarised as follows:

- Pursuant to Rule 30(1) EPC, the filing of a sequence listing was required only if nucleotide or amino acid sequences were disclosed in the application. Accordingly, the Notice from the EPO dated 12 July 2007 concerning the filing of sequence listings (OJ EPO 2007, special edition No. 3, C.2, p. 84) stated that Rule 30(1) EPC governed "disclosures of nucleotide and/or amino acid sequences".

- The term "disclosed" had to be interpreted in the light of Rule 42(1) EPC which stated in sub-paragraph (c) that the description should disclose the invention, whereas in sub-paragraphs (b), (d), (e) and (f) - which dealt with the background art, the figures, the at least one way of carrying out the invention and the way in which the invention was industrially applicable - different terms, i.e. "indicate" and "describe", were used. Accordingly and in line with its dictionary definition, the term "disclose" had to be understood as "to make known; reveal or uncover; allow to be seen; lay open to view". The term could therefore not be used in the context of something that was state of the art.

- The Notice from the EPO of 12 July 2007 also stated in point I.1.2 that "Where the description refers to sequences which belong to the prior art and can be found in publicly available sequence databases, it will not be necessary to include such sequences in the sequence listing". The further statement in the Notice that "Where the claim(s) refer(s) to prior art sequences or where sequences constitute essential features of the invention or are required for the prior art search, those sequences should be incorporated in the sequence listing" was not to be regarded as imposing an obligation in view of the use of the modal verb "should" (instead of "have to" or "must").

- In the present case the application did not literally disclose nucleic acid or amino acid sequences. The claimed diagnostic method did not refer to sequences but rather to biomarkers which were proteins. The biomarkers were listed in Table 1 of the application. These biomarkers as such were prior art, recited by their common names and publicly available under the respective database accession number. Furthermore, according to the description of the patent application, the term "biomarker" was not understood as being limited to the specific sequences publicly available, since these sequences were merely one possibility among many others identifying the structure of the desired biomarker proteins. Due to the difference between the individuals, a protein might be represented by different amino acid sequences which were all allelic variants.

- There was no basis for assuming that the sequences were essential features of the invention. Such an assessment could be made only during substantive examination and was not a task of the Receiving Section. This was confirmed by the fact that the Receiving Section had apparently contacted a "competent" examiner.

- The sequence listing was not required for the prior-art search in the present case.

VIII. The board appointed oral proceedings to be held on 1 February 2013. The annex to the summons contained the board's preliminary opinion on the issues raised by the present appeal. The board expressed the view that the decision under appeal would have to be set aside, the invitation to remedy deficiencies under Rule 30(3) EPC withdrawn, and the late furnishing fee refunded, but that the appeal fee could not be reimbursed.

IX. In response to the summons, the appellant repeated the requests which it had already submitted in the grounds of appeal. It furthermore withdrew the auxiliary request for oral proceedings on the condition that the board decided on the remaining questions as indicated in the annex to the summons.

Reasons for the decision

Admissibility of the appeal

1. The appealed decision did not terminate the procedure up to grant concerning the present patent application. Pursuant to Article 106(2) EPC, it is therefore an admissibility requirement for the present appeal that the decision allowed a separate appeal. The board considers that the formulation "This decision is open to appeal" has to be interpreted as, at least implicitly, allowing a separate appeal. Thus the appeal is considered admissible.

Applicable legal provisions

2. The present appeal concerns a formal requirement which is laid down in Rule 30 EPC and which, if applicable, has to be complied with at the filing date. Accordingly, the appeal has to be assessed on the basis of the legal provisions which were in force at the filing date of the present application, i.e. on 17 February 2010 (for details see J 7/11 of 24 January 2012, point 2 of the Reasons). Thus, apart from Rule 30 EPC itself, the Decision of the President of the EPO dated 12 July 2007 concerning the filing of sequence listings (OJ EPO 2007, special edition No. 3, C.1, p. 26) is of relevance.

Interpretation of Rule 30(1) EPC

3. According to Rule 30(1) EPC, the filing of a sequence listing is required if nucleotide or amino acid sequences are disclosed in a European patent application. A corresponding requirement can be found in Rules 5.2(a) and 13ter.1(a) PCT which use the substantially identical wording "Where the international application contains disclosure of one or more nucleotide and/or amino acid sequences".

4. The crucial issue in the present appeal is the interpretation of the term "disclosed" in Rule 30(1) EPC, namely the question whether a patent application which relates to the use of polypeptides well known in the prior art and which identifies these polypeptides by their common names and by database accession numbers concerning specific representative sequences has to be regarded as "disclosing" amino acid sequences.

5. In ascertaining the meaning of "disclosed" in Rule 30(1) EPC, it appears necessary to consider in more detail the legislative reasons for and the development of the requirement of filing sequence listings.

6. Already before the introduction of Rule 27a EPC 1973 (the predecessor provision of Rule 30 EPC) into the Implementing Regulations, the EPO published a Notice dated 15 November 1989 (Supplement to OJ EPO 12/1989) in which it strongly recommended that from 1 April 1990 patent applications containing nucleic acid and amino acid sequences should use a set of standard symbols and representation methods. In point 3 of the Notice, it was stated:

"Paragraph 1.1 explains what inventions are affected by the rules. Patent applications containing disclosures of nucleotide or amino acid sequences in which the applicant wishes to represent the sequence itself should include these representations in conformity with the standards." (emphasis added)

At that time it was also well-established in the context of Rule 28 EPC 1973 (corresponding to Rule 31 EPC 2000) that a patent applicant who supplemented his written description by the deposit of micro-organisms or other biological material such as plasmids and viruses was not obliged to provide further written information concerning genetic sequences of this material. Such an obligation would have been irreconcilable with the very purpose of the deposit system, i.e. to make it possible to supplement the written description in cases where the biological material could not be described in such a manner as to enable the invention to be carried out by a skilled person. It was furthermore recognised that no deposit was necessary where the biological material was already publicly available, e.g. by means of a previous deposit (see Rule 28(1) EPC 1973).

7. By decision of the Administrative Council of the EPO of 5 June 1992 (OJ EPO 1992, 342) the Implementing Regulations of the EPC were amended inter alia by the insertion of a new Rule 27a which for the first time made sequence listings mandatory for European applications relating to nucleotide and amino acid sequences. New Rule 27a(1) EPC provided that the description had to contain a sequence listing if nucleotide or amino acid sequences were disclosed in the European patent application.

8. The above decision was taken on the basis of Administrative Council document CA/7/92 dated 3 April 1992 which was drawn up by the President of the EPO. This document contained the following passages in points I.2 and 4 of its Part 1 (Explanatory Memorandum):

"The President's decision will make it clear that the sequence listing must contain only those sequences which form part of the claimed invention and not those which are mentioned in the description as belonging to the state of the art."

[...]

If, however, nucleotides or amino acids were originally included in the description only in the form of words, it would be inappropriate to request the applicant to file a sequence listing subsequently as this would inevitably result in new technical information being introduced [emphasis added]. This may well be the case if the applicant has not yet sequenced the nucleotides or amino acids. Rule 27a EPC does not then apply, because the application does not contain any sequences, despite the fact that the invention refers to nucleotides or amino acids."

9. The details of the sequence listing requirement were then laid down in the Decision of the President of the EPO dated 11 December 1992 concerning the representation of nucleotide and amino acid sequences in patent applications and the filing of sequence listings (Supplement No. 2 to OJ EPO 12/1992, p. 1). Its Article 1 stated:

"If the subject-matter of the invention disclosed in a European patent application is nucleotide or amino acid sequences (in German: "Hat die in einer europäischen Patentanmeldung offenbarte Erfindung Nucleotid- oder Aminosäuresequenzen zum Gegenstand") [emphasis added], the description shall contain a sequence listing complying with the WIPO Standard ST.23 reproduced in Annex I."

10. The EPO furthermore published a Notice dated 11 December 1992 (Supplement No. 2 to OJ EPO 12/1992, p. 3) which was intended to supplement the decisions of the Administrative Council and the President of the EPO and to clarify the new rules and the EPC and PCT procedures. In this Notice (see its Section I) the legislative goal of the new provisions was explained as follows:

"The new provisions are intended to ensure that nucleotide and amino acid sequences are presented in a standardised form in European and international applications and to permit systematic EDP-based searches so that the quality of European and international search reports can continue to be guaranteed in the future. Finally, they will make it possible to set up, in co-operation with the United States Patent and Trademark Office (USPTO) and the Japanese Patent Office (JPO), an international patent sequence database which be accessible to the public."

11. The circumstances in which a sequence listing had to be filed were explained in point II.1.2 of the Notice as follows:

"A sequence listing need only be filed for those sequences matching the definition given in WIPO Standard ST.23 paragraph 3(iii) and relating to the invention disclosed in the application.

A sequence listing is not required if the description refers to sequences which belong to the prior art. In this case, however, the sequence must be identified adequately - where applicable, by stating the database accession number - so that it can be found easily." [emphasis added]

12. It can be deduced from these explanations that at the time when new Rule 27a EPC was inserted into the Implementing Regulations and entered into force (on 1 January 1993) the EPO took the view that it was not the legislator's intention to make sequence listings mandatory in situations where the description merely referred to prior-art sequences, e.g. by indicating their common names and database accession numbers. The term "disclosed" in Rule 27a EPC was thus interpreted in a narrow manner in line with the explanatory memorandum in CA/7/92 (see point 8 above) and the established principles concerning the deposit of biological material, according to which no deposit is necessary where the biological material is already publicly available (e.g. by means of a previous deposit), and no genetic sequence information has to be provided when a deposit is made (see point 6 above).

13. In 1998 both the Decision of the President and the Notice from the EPO were replaced by amended versions (see Supplement No. 2 to OJ EPO 1998/11). However, the above-cited passages in Article 1 of the Decision and point II.1.2 of the Notice were not changed in substance.

14. After the revision of the EPC 2000 the Implementing Regulations were amended and Rule 27a EPC 1973 became new Rule 30 EPC 2000. Although amendments were made to the content of the rule, its paragraph (1) remained unchanged apart from the addition of a comma (see OJ EPO 2007, special edition No. 5, p. 45). The travaux préparatoires (see documents CA/PL PV 30 Nos. 88-93 and CA/PL PV 31 Nos. 21-23) do not contain any indication that the legislator intended this paragraph to be understood differently from before. The new Decision of the President dated 12 July 2007 concerning the filing of sequence listings (supra) uses in its Article 1(1) a wording ("If nucleotide or amino acid sequences are disclosed in a European patent application") that mirrors the wording of Rule 30(1) EPC.

15. However, in its updated Notice of 12 July 2007 concerning the filing of sequence listings (which replaced the 1998 version), the EPO interpreted Rule 30(1) EPC not exactly in the same way as it had done before. The relevant passage (see point I.1.2 of the Notice) now read:

"Where the description refers to sequences which belong to the prior art and can be found in publicly accessible sequence databases, it will not be necessary to include such sequences in the sequence listing. [...] Where the claim(s) refer(s) to prior art sequences or where sequences constitute essential features of the invention or are required for the prior art search, those sequences should be incorporated in the sequence listing."

Thus, with respect to prior-art sequences referred to in the application, the 2007 version of the Notice makes a significant distinction. It considers that in certain circumstances a sequence listing is required, in others not.

16. However, the wording of Rule 30(1) EPC does not provide any basis for distinguishing different situations with respect to prior-art sequences referred to in patent applications. No such basis can be found in Article 1(1) of the Decision of the President dated 17 July 2007 either, which in any case could not change the meaning of Rule 30(1) EPC as the higher-ranking legal norm.

17. Furthermore, two of the criteria used as a basis for the distinction (i.e. "constitute essential features of the invention" and "required for the prior art search") seem to require a technical evaluation of the application. However, as rightly observed by the appellant, such a technical examination does not fall within the competence of the Receiving Section (see decisions J 4/85, OJ EPO 1986, 205, J 33/89, OJ EPO 1991, 288, and J 7/97 of 11 December 1997). Rather, the Receiving Section is restricted to a merely formal examination of the sequence listing requirements (see J 7/11 of 24 January 2012, points 9.2 and 15).

18. Hence, only a narrow interpretation of the term "disclosed", in line with the established practice and jurisprudence allowing references to publicly available deposits of biological material, reflects the intention of the legislator at the time when Rule 27a EPC 1973, the predecessor of Rule 30 EPC, was inserted into the Implementing Regulations (see points 6 to 14 above). This means that prior-art sequences do not require the filing of a sequence listing.

19. It follows from the above that the Receiving Section was wrong to apply Rule 30 EPC in the present case. Thus the decision under appeal has to be set aside, the invitation to remedy deficiencies under Rule 30(3) EPC withdrawn, and the late furnishing fee refunded.

Substantial procedural violation

20. The appellant did not submit any arguments in support of its request for reimbursement of the appeal fee. According to Rule 103(1)(a) EPC, such a reimbursement can be ordered only if is equitable by reason of a substantial procedural violation. In the present case the board fails to see any major procedural deficiency in the proceedings before the Receiving Section. In particular it appears that the right to be heard (Article 113(1) EPC) was respected and that the decision was fully reasoned (Rule 111(2) EPC).

21. The appellant argued before the Receiving Section that the invitation under Rule 30(3) EPC had incorrectly stated that a sequence listing had been submitted which did not comply with the relevant rules and that the invitation had to be withdrawn for that reason alone. However, it seems that this erroneous statement did not mislead the appellant since the objection raised by the Receiving Section could be and was correctly understood in view of the further explanations contained in the annex to the invitation (see Sections III and IV above).

22. Therefore the appellant's request for reimbursement of the appeal fee cannot be allowed.

Order

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The invitation to remedy deficiencies under Rule 30(3) EPC is withdrawn.

3. The late furnishing fee is refunded.

4. The request for reimbursement of the appeal fee is refused.

Footer - Service & support
  • Service & support
    • FAQ
    • Contact us
    • Subscription centre
    • Official holidays
    • Publications
    • Procedural communications
    • Ordering
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility